Pasal Wealth › Research › Fabtech Cleanrooms
Small-Cap NSE: FABCLEAN Cleanroom Manufacturing · Pharma Infrastructure · Modular Panels

Fabtech Technologies Cleanrooms Ltd

A modular cleanroom manufacturer for pharma and biotech facilities — demerged from its parent in 2020, renamed twice since, and now holding an export contract with the Botswana Vaccine Institute.

Market Cap
~₹455–690 Cr
Revenue (FY)
₹219–411 Cr
Net Profit (FY)
₹15.8–38.4 Cr
Order Book
~₹354–900 Cr
LinkedIn coverage — link will appear once posted
01

Company Description

Fabtech Technologies Cleanrooms manufactures and provides pre-engineered, pre-fabricated modular panels and cleanroom doors for pharmaceutical, healthcare and biotech facilities — adhering to ISO and FDA standards, covering design, engineering, manufacturing, installation and validation.

The modular-panels division was demerged from its parent (Fabtech Technologies International) in 2020, renamed Fabtech Technologies Cleanrooms Private Limited in January 2021, and only took its current public name in July 2024 — three identities in under four years.

A recent international export contract with the Botswana Vaccine Institute marks its first significant cross-border order — a development that has received almost no coverage outside routine exchange filings.

Management image pending Official company image not available yet · this section will be updated when provided
Management
Chairman & Management
Fabtech Technologies Cleanrooms Ltd · Management Commentary
02
In Their Own Words
Management response pending

We reached out to Fabtech Cleanrooms management with four plain questions. When they respond, answers will appear here in full, unedited, clearly labelled as management's own words.

01. What does your company do, in plain terms?
Management response pending — the company has not provided a direct statement at the time of publication. This section is reserved for the company's own words and future updates.
02. Why should a retail investor take a second look?
Management response pending — the company has not provided a direct statement at the time of publication. This section is reserved for the company's own words and future updates.
03. What do people usually get wrong about the business?
Management response pending — the company has not provided a direct statement at the time of publication. This section is reserved for the company's own words and future updates.
04. What are you building toward for your customers — not the stock?
Management response pending — the company has not provided a direct statement at the time of publication. This section is reserved for the company's own words and future updates.
03

Company Numbers

Source: Public exchange filings and company financial data, as reported. Verify against latest filings before relying on any figure here.

Market Cap
~₹455–690 Cr
Revenue (FY)
₹219–411 Cr
Net Profit (FY)
₹15.8–38.4 Cr
Promoter Holding
~68.5%
Order Book
~₹354–900 Cr
Debtor Days
~182 (high)

Worth watching: Debtor days of ~182 alongside a strong order book — worth tracking cash conversion as international orders (including the Botswana Vaccine Institute contract) scale up, since cross-border payment cycles tend to run longer than domestic ones.

04

Company Performance

Financial figures for Fabtech Cleanrooms are reported across two sources with significant variance — likely reflecting standalone vs consolidated reporting across its demerged entities. The ranges shown reflect this:

Revenue range FY25: ₹219 Cr – ₹411 Cr | Net Profit range: ₹15.8 Cr – ₹38.4 Cr

Verify against the company's own NSE-filed results before drawing conclusions from any single data source.

Source: Public company filings, as reported. These are reported figures, not Pasal Wealth's projections.

+

Why almost nobody's looked at this yet

  • 01Its corporate history is genuinely fragmented. Demerger (2020) → renamed (2021) → renamed again (2024). Three identities in four years is a hard track record to piece together.
  • 02Pharma-adjacent infrastructure suppliers rarely get retail attention. Coverage concentrates on the pharma companies themselves, not the facilities that house them.
  • 03The Botswana Vaccine Institute contract hasn't been widely discussed. A first international order for vaccine manufacturing infrastructure is material — yet it's only in routine filings.